ProCE Banner Activity

iLLUMINATE: Phase III Trial of Ibrutinib + Obinutuzumab vs Chlorambucil + Obinutuzumab in Previously Untreated CLL/SLL

Slideset Download
Conference Coverage
Addition of ibrutinib to obinutuzumab reduced risk of progression or death compared with chlorambucil plus obinutuzumab, including in patients with bulky disease and high-risk cytogenetics.

Released: December 17, 2018

Expiration: December 16, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology